Therapeutic applications of histone deacetylase inhibitors in sarcoma

Area of Science:

• Oncology
• Epigenetics
• Pharmacology

Background:

• Sarcomas are rare cancers originating from mesenchymal stem cells with limited treatment options.
• Current treatments like surgery, radiation, and chemotherapy have low response rates and significant side effects, including chemoresistance.
• There is a critical need for novel therapeutic strategies to improve sarcoma treatment outcomes.

Purpose of the Study:

• To review the current understanding and therapeutic applications of Histone deacetylase inhibitors (HDAC inhibitors) in sarcoma treatment.
• To summarize the mechanisms by which HDAC inhibitors affect sarcoma growth and progression.
• To evaluate the potential of HDAC inhibitors as monotherapy and in combination regimens for sarcomas.

Main Methods:

• Review of preclinical studies investigating HDAC inhibitors in various sarcoma models.
• Analysis of data from Phase I and II clinical trials assessing HDAC inhibitors in sarcoma patients.
• Evaluation of the synergistic effects of HDAC inhibitors with standard chemotherapy and radiotherapy.

Main Results:

• HDAC inhibitors demonstrate efficacy in inhibiting sarcoma growth both in vitro and in vivo.
• HDAC inhibitors work through multiple pathways, including inducing apoptosis, cell cycle arrest, and reducing invasion and metastasis.
• Preclinical data suggest HDIs can sensitize sarcomas to chemotherapy and radiotherapy, enhancing treatment responses.
• Clinical trials indicate that combination regimens involving HDAC inhibitors are more promising than monotherapy for sarcomas.

Conclusions:

• HDAC inhibitors represent a promising class of epigenetic modifying agents for sarcoma treatment.
• Combination therapies utilizing HDAC inhibitors alongside standard treatments or targeted drugs show significant potential.
• Further clinical investigation is warranted to optimize the use of HDAC inhibitors in sarcoma management.